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S U M M A R Y
Objectives: The prevalence of infectious diseases is increasing in developing countries, and this may
threaten the biological safety of donated blood. This study analyzed trends in the prevalence of
transfusion-transmissible infectious pathogens among Chinese, ﬁrst-time, voluntary blood donors from
1999 to 2009 to evaluate the potential for disease transmission.
Methods: From 1999 to 2009, all ﬁrst-time donors at the Xi’an Blood Service (XBS) were screened for
hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeﬁciency virus (HIV), and syphilis
infections using enzyme-linked immunosorbent assays (ELISA); results were conﬁrmed using
alternative commercial kits. The prevalence and temporal trends were analyzed using the Cochran–
Armitage trend test and other appropriate methods.
Results: From 1999 to 2009, 263 299 ﬁrst-time blood donors were analyzed. The overall prevalence rates
were 1.16% for HBV, 0.51% for HCV, 0.02% for HIV, and 0.31% for syphilis. There was a signiﬁcant decrease
in the trend for HBV and HCV infections, while a signiﬁcant increase was found for syphilis. The
prevalence of HIV infection remained low and stable during the study period.
Conclusions: These ﬁndings suggest that HBV infection is the primary threat to blood safety, while the
increasing prevalence of syphilis might also be a potential threat.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Blood products, such as blood components for both transfusions
and plasma derivatives, are essential therapeutics in modern
medicine. Red blood cell transfusions are vital in saving lives
during emergencies and in other cases where interventions are
necessary.1 For example, blood coagulation factor concentrates
dramatically improve the life expectancy and quality of life of
hemophilia patients. Until recently, blood products were consid-
ered to be purely physiological materials that were not expected to
be harmful. However, during the early 1990s in Henan Province of
China, a large number of human immunodeﬁciency virus (HIV)* Corresponding authors. Tel./Fax: +86 29 84775470; Tel./fax: +86 29 84774872.
E-mail addresses: bestar@fmmu.edu.cn (Q.-X. An), zhjshao@hotmail.com
(Z.-J. Shao).
1 These authors contributed equally to the work.
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.10.006cases were found in people who had previously been paid to
donate blood.2 In addition to HIV, hepatitis B virus (HBV) and
hepatitis C virus (HCV) were found to be associated with blood
transfusions in Chinese adults.3–5
The safety of the blood supply can be estimated by monitoring
the prevalence of viral markers in the donor population. A higher
prevalence of donations containing infectious contaminants is
found in ﬁrst-time blood donors compared to repeat donors.
Therefore, the evaluation and monitoring of these viruses in ﬁrst-
time blood donors is essential for controlling the potential risk of
transfusion-transmissible infections (TTIs).6 Long-term trends in
the rates of infectious diseases among blood donors may also
reﬂect trends in the population risk. Each year the Xi’an Blood
Service (XBS) collects more than 20 000 blood units from ﬁrst-time
blood donors, and since 1999, has maintained a research database
of all blood donations, including all test results. The database
provides a unique opportunity for monitoring the trends in blood-
borne infections among blood donors over time. In this study,ses. Published by Elsevier Ltd. All rights reserved.
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antibodies to HCV (anti-HCV), and antibodies to HIV (anti-HIV),
over an 11-year period (1999 through 2009) were evaluated by
analyzing the screening test data from allogeneic blood donations
at XBS.
2. Methods
The XBS covers 17 regions located across Shaanxi Province,
China. All of the XBS regions use standard blood donor recruitment
and donation testing procedures. The XBS headquarters in Xi’an,
the capital of Shaanxi Province, collects and records blood
donations from all of the regions and manages these records in
a centralized database. The data analyzed in this report were
extracted from the XBS database. The data obtained from the XBS
database were examined for any duplications, which were
subsequently removed, and checked for any missing values, and
then supplemented with conﬁrmatory test results.
For the purpose of this study, data from 263 299 ﬁrst-time
whole-blood donors obtained from 1999 to 2009 were analyzed. A
ﬁrst-time donor was deﬁned as a donor who had not previously
donated blood according to the blood center’s current records or
according to the person’s own report. The donations were all
screened for HBsAg, anti-HCV, anti-HIV-1/2 or HIV antigen/
antibody, and anti-Treponema pallidum (anti-TP) using enzyme-
linked immunosorbent assays (ELISA) in accordance with the
standard operating procedures at each center, using the same
commercial kits approved by the Ministry of Health of the People’s
Republic of China; results were conﬁrmed with alternative
commercial kits (Table 1). The tests used included a monoclonal
neutralization assay for HBV, an enzyme immunoassay method
with an alternative assay for HCV, Treponema pallidum particle
agglutination assays for syphilis, and an ELISA repeated in
duplicate followed by a Western blot for HIV (Table 1). A
double-positive donor who was conﬁrmed as being truly positive
was permanently disqualiﬁed from further donation and was
invited for free counseling and follow-up. Vaccinations were
recommended for the immediate family members of HBsAg-
positive donors.
To deﬁne the prevalence of TTIs, the number of TTI-positive
donations during each year was divided by the total number of
blood donations that year, and the 95% conﬁdence interval (CI) was
calculated using a binomial distribution. The prevalence across
different years was compared using the Chi-square test. The
Cochran–Armitage trend test (Z) was used to determine any
signiﬁcant trends in the rates of infected donations over time.7–9
Statistical signiﬁcance was set at p < 0.05. All statistical tests were
performed using SAS 9.1 (SAS Institute, Cary, NC, USA).
3. Results
The data collected from XBS showed that there was a total of
263 299 ﬁrst-time donations that were tested in the XBS
laboratories during the 11-year period under study. The majorityTable 1
Screening tests and conﬁrmatory test kits (1999–2009)
Test items Screening tests 
HBsAg (1999–2009) HBsAg test (Lizhu Diagnost
Anti-HCV(1999–2009) Anti-HCV (Beijing Wantai, 
Anti-HIV-1/2 (1999–2004) Anti-HIV-1/2 (Beijing Wan
HIV antigen/antibodya (2005–2009) HIV antigen/antibody (Beij
Anti-TP (1999–2009) Anti-TP (Lizhu Diagnostics
HBsAg, hepatitis B surface antigen; anti-HCV, antibody to hepatitis C virus; anti-HIV, ant
EIA, enzyme immunoassay.
a The HIV antigen/antibody combo assays replaced the antibody-only EIA in 2005.of the donors were men (64.48%), and 84.65% were under 40 years
of age. In the XBS database there was a total of 3057 conﬁrmed
HBsAg-positive donations, 1352 conﬁrmed anti-HCV-positive
donations, and 41 conﬁrmed anti-HIV-positive donations among
the 263 299 ﬁrst-time donors between 1999 and 2009. Tables 2
and 3 show the prevalence rates of the infectious disease markers
HBsAg, anti-HIV, and anti-HCV that were conﬁrmed among ﬁrst-
time whole-blood donors by sex and age. The overall prevalence
was 1.16% for HBV (95% CI 1.12–1.20%), 0.51% for HCV (95% CI
0.49–0.54%), 0.02% for HIV (95% CI 0.01–0.03%), and 0.31% for
syphilis (95% CI 0.29–0.33%) (Table 2). HBV infection was the most
common reason for donor disqualiﬁcation from donating blood
(approximately 70%).
The prevalence rates of HBsAg decreased over time among both
sexes, except in 2001. After controlling for age and gender, we
found that HBV infection was more common in men (1.26%, 95% CI
1.20–1.31%) than in women (1.00%, 95% CI 0.93–1.06%) (Chi-
square = 33.76, p < 0.0001), and both men and women in the 30–
39 years age group had the highest prevalence of HBV infection.
The prevalence in men was signiﬁcantly higher than in women in
the 30–39, 40–49, and >50 years age groups (p < 0.05). The
prevalence of HBV decreased with age in women, with the highest
prevalence observed in the <29 years age group (1.07%, 95% CI
0.98–1.16%) and the lowest prevalence observed in the >50 years
age group (0.67%, 95% CI 0.40–1.04%). The prevalence of HBV
decreased over time (Z = 33.88, p < 0.0001), peaking in 2001
(2.74%, 95% CI 2.53–2.96%) and decreasing rapidly until 2004. The
prevalence of HBV was stable between 2005 and 2009 (Table 2).
Overall the prevalence of HBsAg decreased dramatically over the
11 years, from 1.88% (95% CI 1.69–2.09%) in 1999 to 0.59% (95% CI
0.52–0.68%) in 2009.
Anti-HCV prevalence rates decreased over time in both sexes.
HCV prevalence in blood donors showed a gradual decline, from
1.14% in 1999 to 0.42% in 2009 (Z = 13.88, p < 0.0001). HCV
infection in women (0.63%, 95% CI 0.58–0.68%) was signiﬁcantly
higher than in men (0.45%, 95% CI 0.42–0.48%) (Chi-square = 38.12,
p < 0.0001) (Table 3). After controlling for both age and gender, we
found that men in the 40–49 years age group (0.80%, 95% CI 0.67–
0.94%) and women in the 30–39 years age group (0.94%, 95% CI
0.81–1.08%) had the highest prevalence of HCV. The prevalence of
HCV in men in the 30–39 years age group (0.63%, 95% CI 0.55–
0.72%) was signiﬁcantly lower than that in women (0.94%, 95% CI
0.81–1.08%) in the same age group (Chi-square = 16.14,
p < 0.0001). In general, HCV prevalence decreased by 6.32%
(0.072% of the original prevalence) per year between 1999 and
2009.
The prevalence of HIV infection was low and stable during the
research period (Z = 1.24, p = 0.21), and there were no statistically
signiﬁcant differences observed among any of the age and gender
groups. Males older than 50 years had a slightly higher HIV
prevalence than those in the other age groups.
A signiﬁcant increase in syphilis prevalence was observed
(Z = 3.26, p = 0.001). Men in the 40–49 years age group (0.73%, 95%
CI 0.61–0.86%) and women in the >50 years age group (0.60%, 95%Conﬁrmatory tests
ics, China) HBsAg test (DiaSorin, Italy)
China) Anti-HCV (DiaSorin, Italy)
tai, China) Anti-HIV-1/2 (Bio-Rad, France)
ing Wantai, China) HIV antigen/antibody (Bio-Rad, France)
, China) Anti-TP (Fujirebio Diagnostics, Japan)
ibody to human immunodeﬁciency virus; anti-TP, antibody to Treponema pallidum;
Table 2
Positive rates for HBsAg, anti-HCV, anti-HIV, and anti-TP in donations in Xi’an, 1999–2009
Year Total
screened












1999 17 754 1.88 1.69–2.09 1.14 0.99–1.31 0.04 0.02–0.08 0.10 0.06–0.15
2000 19 297 2.31 2.10–2.53 0.68 0.57–0.81 0.02 0.00–0.05 0.07 0.04–0.12
2001 22 460 2.74 2.53–2.96 0.83 0.72–0.96 0.00 0.00–0.02 0.36 0.28–0.44
2002 23 300 2.17 1.99–2.37 0.55 0.46–0.65 0.00 0.00–0.02 0.43 0.35–0.52
2003 18 814 1.53 1.36–1.71 0.60 0.50–0.72 0.02 0.00–0.05 0.38 0.29–0.48
2004 22 174 0.65 0.55–0.76 0.42 0.34–0.51 0.02 0.00–0.05 0.41 0.33–0.50
2005 19 707 0.61 0.51–0.73 0.36 0.28–0.45 0.01 0.00–0.04 0.31 0.24–0.40
2006 23 169 0.40 0.32–0.49 0.32 0.25–0.40 0.01 0.00–0.03 0.23 0.18–0.30
2007 27 621 0.42 0.34–0.50 0.42 0.35–0.51 0.00 0.00–0.01 0.36 0.29–0.44
2008 32 967 0.56 0.48–0.64 0.25 0.20–0.31 0.00 0.00–0.01 0.33 0.27–0.40
2009 36 036 0.59 0.52–0.68 0.42 0.36–0.50 0.05 0.03–0.08 0.30 0.25–0.36
Total 263 299 1.16 1.12–1.20 0.51 0.49–0.54 0.02 0.01–0.03 0.31 0.29–0.33
Statistic (Z)a 33.8849 13.8793 1.2427 3.2631
Two sided p > jZj <0.0001 <0.0001 0.2140 0.0011
HBsAg, hepatitis B surface antigen; anti-HCV, antibody to hepatitis C virus; anti-HIV, antibody to human immunodeﬁciency virus; anti-TP, antibody to Treponema pallidum;
95% CI, 95% conﬁdence interval.
a Cochran–Armitage trend test.
Z.-H. Ji et al. / International Journal of Infectious Diseases 17 (2013) e259–e262 e261CI 0.35–0.96%) had the highest prevalence of syphilis. The
prevalence of syphilis in women in the <29 years age group
(0.26%, 95% CI 0.21–0.30%) was signiﬁcantly higher than that in
men in the same age group (0.16%, 95% CI 0.13–0.18%) (Chi-
square = 18.78, p < 0.0001).
4. Discussion
In developed countries, the blood supply is safe due to a
combination of donor education, donor screening, willingness to
donate, and strict laboratory testing procedures. Therefore, the risk
of transfusion-transmitted viral infections is extremely low in
these countries.10 However, in East Asia, and particularly China
where the HBV prevalence is high and the HCV and HIV prevalence
rates are rapidly increasing, the safety of the blood supply is
threatened.11–14 Simultaneously, because of a shortage in the
blood supply or low family income, the practice of paying for blood
donation has not been eliminated in some regions, despite a blood
donation law that became effective in 1998.5 Therefore, screeningTable 3











<29 117 375 1.10 1.04–1.16 0.35 
30–39 30 936 1.74 1.60–1.89 0.63 
40–49 17 460 1.44 1.27–1.63 0.80 
>50 4003 0.97 0.69–1.33 0.52 
Total 169 774 1.26 1.20–1.31 0.45 
Female
<29 52 839 1.07 0.98–1.16 0.43 
30–39 21 734 0.99 0.87–1.13 0.94 
40–49 16 113 0.83 0.70–0.98 0.79 
>50 2839 0.67 0.40–1.04 0.92 
Total 93 525 1.00 0.93–1.06 0.63 
Both male and female (years)
<29 170 214 1.09 1.04–1.14 0.38 
30–39 52 670 1.43 1.33–1.54 0.76 
40–49 33 573 1.15 1.04–1.27 0.80 
>50 6842 0.85 0.64–1.09 0.69 
Total 263 299 1.16 1.12–1.20 0.51 
HBsAg, hepatitis B surface antigen; anti-HCV, antibody to hepatitis C virus; anti-HIV, ant
95% CI, 95% conﬁdence interval.for risk factors and monitoring blood markers has been employed
in China to guarantee the safety of the blood supply. Here, we
report for the ﬁrst time the prevalence of HBV, HCV, HIV, and
syphilis infections during the period 1999–2009 to examine the
potential threat and to evaluate the trends of major infectious
diseases in ﬁrst-time blood donors in northwestern China.
The results of this study clearly demonstrate a declining trend
in the prevalence of HBV and HCV in donations from 1999 to 2009.
Similar declines have been reported among blood donors from
western countries, such as the UK (1993–2001) and the USA
(1995–2002),15,16 as well as developing countries such as Iran
(2004–2007).6,17 The underlying causes for this decrease may be
related to an increased awareness of blood-borne diseases,
voluntary deferral by potential high-risk donors, and an improve-
ment in the recruitment, retention, and screening of donors.
Finally, hepatitis B immunization programs may also have played
an important role in decreasing the occurrence of hepatitis B,









0.32–0.39 0.01 0.00–0.02 0.16 0.13–0.18
0.55–0.72 0.03 0.01–0.05 0.52 0.45–0.61
0.67–0.94 0.03 0.01–0.07 0.73 0.61–0.86
0.33–0.80 0.05 0.01–0.18 0.55 0.34–0.83
0.42–0.48 0.02 0.01–0.02 0.29 0.27–0.32
0.38–0.49 0.02 0.01–0.03 0.26 0.21–0.30
0.81–1.08 0.01 0.00–0.03 0.48 0.39–0.58
0.66–0.94 0.03 0.01–0.07 0.35 0.26–0.45
0.60–1.34 0.00 0.00–0.13 0.60 0.35–0.96
0.58–0.68 0.02 0.01–0.03 0.33 0.30–0.37
0.35–0.41 0.01 0.01–0.02 0.19 0.17–0.21
0.69–0.84 0.02 0.01–0.03 0.51 0.45–0.57
0.70–0.90 0.03 0.01–0.05 0.55 0.47–0.63
0.51–0.91 0.03 0.00–0.11 0.57 0.41–0.78
0.49–0.54 0.02 0.01–0.02 0.31 0.29–0.33
ibody to human immunodeﬁciency virus; anti-TP, antibody to Treponema pallidum;
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1.20/100 persons), which is much higher than rates reported from
the same region, including Japan, with a reported HBV infection
rate of 2.78 per 100 000 persons per year (95% CI 1.78–4.14/
100 000 persons). In some regions with lower infection rates, such
as Canada (1990–2000) and northern India (1997–2002), a stable
prevalence of HBV infection among blood donors has also been
reported.18,19 Therefore, the high level of HBV infection in the
Chinese general population suggests that this pathogen poses a
signiﬁcant risk to the blood supply.
In China, HCV infection is more prevalent than in several
developed countries, but is less prevalent than HBV infection in
the general population. In previous studies, the prevalence of HCV
has been reported to be between 0.33% and 0.90% in blood donors
from China.20–22 In this study, HCV prevalence showed a gradual
decline from 1.14% (95% CI 0.99–1.31%) in 1999 to 0.42% (95% CI
0.36–0.50%) in 2009. The prevalence of HCV was estimated to be
3.2% in the Chinese general population in 1993,23 which is
approximately 6.3-fold higher than that observed in the Chinese
blood donors. This difference could be due to the self-selection of
blood donors or may reﬂect the effectiveness of pre-donation
screening.
The prevalence of HIV showed less obvious trends. The number
of people in China living with HIV/AIDS at the end of 2003 was
estimated to be 840 000 (650 000–1 020 000), with a prevalence of
0.07% in the general population (95% CI 0.05–0.08%). Each year,
more cases have been reported throughout the country.24 The
prevalence of HIV in blood donations was 0.02% in the present
study. Therefore, it is worth noting that despite a rise in infections
in the general population, the prevalence remains steady among
ﬁrst-time blood donors. This result is consistent with reports from
the USA (0.012%, 2002),16 England (0.0047%, 1993–2001),15 Iran
(0.005%, 2004–2007),6 and Eastern European countries (0.037%,
2004).25
After a massive syphilis epidemic in the ﬁrst half of the 20th
century, syphilis was eliminated for 20 years (1960–80). However,
substantial changes in Chinese society have contributed to a
resurgent epidemic of sexually transmitted diseases since the
1980s.26,27 The reported incidence rate of syphilis in the general
population jumped from 4.73 per 100 000 persons in 1999 to 23.07
per 100 000 persons in 2009.28 This study suggests that the syphilis
epidemic in China is also present in the donor population. The
Chinese government has issued a working plan that calls for public
awareness campaigns, increased clinical screening, and free
standardized treatment for syphilis patients, which should help
prevent the spread of syphilis in the general and donor
populations.
In conclusion, although a declining trend was found in the
prevalence of HBV and HCV in blood donations from 1999 to 2009,
HBV infection remains the primary threat to blood safety. A
resurgent epidemic of sexually transmitted diseases that began in
the 1980s and includes syphilis might be a potential threat to blood
safety; further measures for monitoring and detecting syphilis are
urgently needed.
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